Polycystin-2 Associates With Malignancy in Meningiomas.

Area of Science:

• Neuro-oncology
• Molecular Biology
• Cell Biology

Background:

• Polycystin-2 (PC2) is implicated in cell survival pathways and its aberrant expression is linked to various cancers.
• PC2 expression patterns in meningiomas, a common primary brain tumor, remain uncharacterized.

Purpose of the Study:

• To investigate PC2 expression levels in meningiomas.
• To compare PC2 expression in meningiomas with normal brain tissue.
• To assess the association of PC2 expression with meningioma grade, recurrence, and patient survival.

Main Methods:

• Quantitative immunohistochemistry was used to analyze PC2 protein expression in 82 meningioma samples (60 benign, 22 high-grade) and normal leptomeninges.
• PC2 messenger RNA (mRNA) levels were quantified using real-time polymerase chain reaction (RT-PCR).
• Labeling index and gene expression data were correlated with tumor grade, recurrence status, and survival outcomes.

Main Results:

• PC2 immunostaining was absent in normal leptomeninges but detected in meningiomas.
• PC2 mRNA levels were significantly increased in WHO grade 1 and grade 2 meningiomas compared to normal brain tissue.
• PC2 expression, assessed by both IHC and RT-PCR, showed a significant positive correlation with increasing malignancy grade and with tumor recurrence.
• Recurrent meningiomas exhibited higher PC2 levels than primary tumors.

Conclusions:

• PC2 expression is upregulated in meningiomas and associated with higher tumor grade and recurrence.
• While no direct correlation with overall survival was found, a trend suggested longer survival in high-grade tumors with low PC2 expression.
• These findings suggest a potential role for PC2 in meningioma pathogenesis, necessitating further research into its underlying mechanisms.